Sobrevida de pacientes com câncer de próstata

Fabienne Camilo da Silveira Pirajá; Rafael Bandeira Lages; Uylma Assunção Costa; João Batista Mendes Teles; Viriato Campelo

doi:10.5020/18061230.2013.2617

Authors

Fabienne Camilo da Silveira Pirajá Universidade Federal do Piauí - UFPI
Rafael Bandeira Lages Universidade Federal do Piauí - UFPI
Uylma Assunção Costa Universidade Federal do Piauí - UFPI
João Batista Mendes Teles Universidade Federal do Piauí - UFPI
Viriato Campelo Universidade Federal do Piauí - UFPI

DOI:

https://doi.org/10.5020/18061230.2013.2617

Keywords:

Prostatic Neoplasms, Survival Analysis, Prostatic Diseases.

Abstract

Objective: To analyze the survival after five years among patients treated of prostate cancer at Hospital São Marcos. Methods: A descriptive population-based epidemiological study performed in Teresina-PI, evaluating a hospital cohort consisting of 71 patients of Hospital São Marcos, enrolled in Hospital Cancer Registry (HCR) from 2000 to 2001, under ICD10 -C61. The variables considered in the evaluation of survival were: age group, tumor staging and skin color. The Kaplan-Meier method was used in the calculation of survival functions in five years and the Kruskal-Wallis test in comparison between variables. Results: The specific survival rate for prostate cancer was of 78.5% in five years. The death risk in this study increased with age and advanced stage at diagnosis (aged 80 or above = 60%; and stage IV = 63%). The Kruskal-Wallis test showed no statistically significant variation between groups. Conclusion: The age and advanced stage at diagnosis decreased patients’ survival.

Downloads

Download data is not yet available.

References

Ministério da Saúde (BR), Instituto Nacional de Câncer. A situação do câncer no Brasil. Rio de Janeiro:INCA; 2006.

World Health Organization - WHO. Are the number of câncer cases increasing or decreasing in the world?Disponível em: http://www.who.int/features/qa/15/en/index.html. Acessado em 06 de setembro de 2001.

Tonon TCA, Schoffen JPF. Câncer de próstata:uma revisão da literatura. Rev Saúde Pesquisa.2009;2(3):403-10.

Ministério da Saúde (BR), Instituto Nacional de Câncer.Estimativa 2010: incidência do câncer no Brasil. Rio de Janeiro: INCA; 2009.

Bailar III JC, Gornik HL. Cancer undefeated. N Engl J Med. 1997;336:1569-74.

Wünsch Filho V, Moncau JE. Mortalidade por câncer no Brasil 1980-1995: padrões regionais e tendências temporais. Rev Assoc Med Bras. 2002; 48(3):250-7.

Bouchardy C, Fioretta G, Rapiti E, Verkooijen HM,Rapin CH, Schmidlin F, et al. Recent trends in prostate cancer mortality show a continuous decrease in several countries. Int J Cancer. 2008;123(2):421-9.

Fonseca LAM, Eluf Neto J, Wünsch Filho V.Tendências da mortalidade por câncer nas capitais dos estados do Brasil, 1980-2004. Rev Assoc Med Bras. 2010;56(3):309-12.

Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 1999;83(1):18-29.

Laurenti R, Jorge MHPM, Gotlieb SLD. Perfil epidemiológico da morbi-mortalidade masculina.Ciênc Saúde Coletiva. 2005;10(1):35-46.

Baade PD, Coory MD, Aitken JF. International trends in prostate-cancer mortality: the decrease is continuing and spreading. Cancer Causes Control. 2004;15(3):237-41.

Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC, et al. Cancer surveillance series:interpreting trends in prostate cancer-part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst. 1999;91(12):1017-24.

Guerra MR, Gallo CVM, Mendonça GAS. Risco de câncer no Brasil: tendências e estudos epidemiológicos mais recentes. Rev Brasi Cancerol. 2005;51(3):227-234.

Quinn M, Babb, P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality.Part II: individual countries. BJU Int. 2002;90(2):174-84.

Neal DE, Donovan JL, Martin RM, Hamdy FC.Screening for prostate cancer remains controversial.Lancet. 2009;374(9700):1482-3.

Schroder FH, Hugosson J, Roobol MJ. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320–28.

Gonçalves IR, Padovani C, Popim RC. Caracterização epidemiológica e demográfica de homens com câncer de próstata. Ciênc Saúde Coletiva 2008;13(4):1337-42.

Vercelli M, Quaglia A, Marani E, Parodi S. Prostate cancer incidence and mortality trends among elderly and adult Europeans. Crit Rev Oncol Hematol.2000;35(2):133-44.

Migowski A, Silva GA. Sobrevida e fatores prognósticos de pacientes com câncer de próstata clinicamente localizado. Rev Saúde Pública. 2010;44(2):344-52.

Dall’oglio MF, Crippa A, Antunes AA, Nesrallah LJ,Leite KR, Srougi M.. Survival of patients with prostate cancer and normal PSA levels treated by radical prostatectomy. Int Braz J Urol. 2005;31(3):222-7.

Stanford JL, Stephenson RA, Coyle LM, Cerhan J, Correa R, Eley JW, et al. Prostate Cancer Trends 1973-1995, SEER Program, National Cancer Institute.Bethesda, MD; 1999.

Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, et al. Cancer survival in five continents: a worldwide population-based study(CONCORD). Lancet Oncol. 2008;9(8):730-56.

Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality.Rev Int J Cancer. 2000;85:60-67.

Moul, J. W., Douglas, T. H., McCarthy, W. F. and McLeod, D. G. Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. J Urol. 1996;155(5):1667-73.

Roach M 3rd, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Grignon D. Race and survival of men treated for prostate cancer on radiation therapy oncology group phase III randomized trials. J Urol. 2003;169(1):245-50.

Chu KC, Tarone RE, Freeman HP. Trends in prostate cancer mortality among black men and white men in the United States. Cancer. 2003;97(6):1507-16.